Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Telia Company in agreement to sell Telia Latvia to Tet

· Telia Company in agreement to sell 100% of the shares in Telia Latvia – a leading B2B telecom services provider – to Tet following an open auction process · Sales price corresponds to an enterprise value of EUR 10.75 million on a cash and debt free basis, representing a FY 2021e EV/EBITDA multiple of 10x · Telia Company remains committed to Latvia with its 49% ownership in the fixed network operator Tet and 60.3% ownership in the mobile network operator LMT Telia Company has today entered into an agreement to sell its 100% ownership in Telia Latvija SIA (“Telia Latvia”) to Tet

Tetra Pak awards BillerudKorsnäs for being ahead in fighting climate change

BillerudKorsnäs has been awarded the Climate Prize as part of the supplier engagement initiative “Join us in protecting the planet”, driven by Tetra Pak. The company, which is one of BillerudKorsnäs’ most important customers, launched this initiative last year to create a movement aimed to accelerate sustainability actions across its value chain.“We commit to making safe food available, everywhere. And we promise to do that in a way that protects what’s good: protecting food, people and the planet. In order to shape the future with secure and sustainable food systems we are decarbonizing

Fred. Olsen Windcarrier - Contract updates

Fred. Olsen Windcarrier (FOWIC) has recently executed three new contracts and reservation agreements with a combined revenue of up to EUR 80m. The contracts will cover approximately 300 days in 2022 and 200 days in 2023, in both Europe and APAC. Two contracts are linked to projects where FOWIC is already involved.  Following these new contracts, FOWIC’s total revenue backlog stands at approx. EUR 355m of which 18% is linked to options. The yearly distribution of the backlog is 2022: EUR 152m, 2023: EUR 126m and 2024: EUR 77m. In accordance with the previously announced vessel upgrade

BioStock: WntResearch’s Foxy-5 shows potential in leukemia

In parallel with the ongoing phase II study in colon cancer, WntResearch is also evaluating other potential target indications for the drug candidate Foxy-5. In collaboration with a Brazilian team of researchers, acute myeloid leukemia is now being identified as a possible indication, resulting in a patent application being filed. BioStock contacted CEO Anders Rabbe to find out more about what this means for the company.Read the full article at biostock.se:https://www.biostock.se/en/2022/01/wntresearchs-foxy-5-shows-potential-in-leukemia/This is a press release from BioStock -

Incoax Networks AB announces the outcome for exercising warrants of series 2021

The period for exercising warrants of series 2021 ("Warrants") for subscription of shares in Incoax Networks AB (publ) ("InCoax" or "the Company") ended on December 31, 2021. A total of 9,047,114 Warrants were exercised for 4,523,557 shares, corresponding to an exercise rate of approximately 99 percent, and the Company receives approximately SEK 22.6 million before issue costs.Two (2) Warrants entitled to subscription of one (1) new share in the Company against cash payment of SEK 5 per share during the period December 1, 2021, through December 31, 2021. The Company today announces that 9,

Nordnet: Monthly statistics December

In December, 5,123,800 trades were made in listed financial instruments among Nordnet’s customers, which corresponds to 246,800 trades per day. New customers in December was 21,500, and the number of new customers in 2021 is 379,400. The total number of customers at the end of December was 1,600,900. Net savings for December was SEK 6.2 billion and the total net savings during 2021 is SEK 83.5 billion. The savings capital was SEK 802 billion and lending amounted to SEK 25.4 billion at the end of December. December November Change  December Change

ExpreS2ion announces further positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine

Hørsholm, Denmark, January 4, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated proof-of-concept also in HER2-transgenic preventive as well as therapeutic tumor mice models. The vaccine has thus reached a further important pre-clinical milestone. These are very important headline results as the therapeutic vaccine is being developed towards first in human clinical investigations in 2023.The additional topline preclinical results

Launch of share buyback programme

Company announcement 1/2022 With reference to company announcement no. 21/2021 dated 5 November 2021, The Board of Directors of HusCompagniet A/S (“HusCompagniet”) has decided to initiate a share buyback programme of up to DKK 40 million for the purpose of returning value to the shareholders and meet obligations relating to HusCompagniets incentive programmes. The programme will run for the period 4 January 2022 – 31 March 2022, and any shares not used for incentive programmes will be proposed cancelled. No dividend is expected to be paid out on any treasury shares.  Including the

25.3M€ worth of loans were facilitated in December

FELLOW FINANCE PLC PRESS RELEASE 4.1.2022 AT 9:00 AMIn December, Fellow Finance's loan investors funded business and consumer loans worth of 25.3M€. The cumulative loan volume grew to 910 million euros and the total number of loan investors to 18 927 customers. The statistics of the service, including the return development, can be followed on the company's website www.fellowfinance.fi/investor/investor-statistics. The return development considers borrowers' payment behaviors including gained interest on invested capital, realized credit losses and the changes in the credit loss

CapMan Nordic Real Estate fund exits several properties

CapMan Real Estate press release 4 January 2022 at 9:00 a.m. EET CapMan Nordic Real Estate fund exits several properties CapMan Nordic Real Estate Fund, a 2013-vintage value-add fund, has signed and closed several exits recently. The fund will start distributing carried interest once these exits are completed. At the end of December, the fund exited Vesterbrogade 80, a 7,955 sqm mixed-use property in central Copenhagen originally acquired in 2015, to COPI. The building has been refurbished under CapMan’s ownership with conversion of the currently unused attic space

Volvo’s heavy-duty electric truck is put to the test: excels in both range and energy efficiency

Now the first independent energy efficiency test with a fully loaded heavy-duty electric Volvo truck has been done in Germany. The electric truck exceeded its official range and used 50% less energy than its diesel counterpart.Watch Volvo FH Electric being tested here.  The tested truck was a Volvo FH Electric , a zero-exhaust emission vehicle with 490 kW of continuous power and a gross combination weight of 40 tonnes. The German trucking journalist Jan Burgdorf tested the truck

RaySearch signs agreement with Proton International Arkansas to provide RayStation at the UAMS Radiation Oncology Center

RaySearch has signed an agreement for RayStation®* with Proton International Arkansas for the Radiation Oncology Center, which is part of the University of Arkansas for Medical Scienses (UAMS) Winthrop P. Rockefeller Cancer Institute.The UAMS Radiation Oncology Center will open in 2023 and be the first proton center in the state of Arkansas. It will use RayStation treatment planning system. The software selected by Proton International Arkansas include advanced technologies such as IMPT (intensity modulated proton therapy), multi-criteria optimization, and full adaptive planning

Hydrogen centre financed by the Swedish Energy Agency

The centre of excellence TechForH2 has been awarded a grant from the Swedish Energy Agency for the time period 2022-2026. TechForH2 is led by Chalmers University of Technology and will be a collaboration with partners such as RISE, Siemens Energy, PowerCell Sweden, Scania, Volvo GTT, GKN Aerospace, Oxeon, Stena Teknik, Johnson Matthew and Insplorion. The total budget is ca. 162 MSEK over the first five-year period.The Swedish Energy agency has granted eleven new centres of excellence, with the overall goal to boost world-class research and innovation in areas of strategic importance for a

NCC to construct Stationshusen in Märsta

NCC, in partnership with Sigtunahem, will construct a new residential block at Sätuna torg in Märsta, Sigtuna Municipality. The project is a turnkey contract with an order value of approximately SEK 300 million. Image: Sigtunahem Sätuna torg is located in central Märsta. The construction of Stationshusen is the starting shot for the urban development that is being planned in the area adjacent to Märsta rail station. A new town square with a mix of rental units, tenant-owner apartments, commercial activities and services will emerge here. “We have had a close, creative

Skanska divests office portfolio in Wroclaw and Krakow, Poland, for about EUR 128M, about SEK 1.3 billion

Skanska has divested a portfolio of two office projects in Wroclaw and Krakow, Poland, for EUR 128M, about SEK 1.3 billion. The buyer is Stena Real Estate BV. The transaction will be recorded by Skanska Commercial Development Europe in the first quarter of 2022. The transfer of the properties is scheduled for the second quarter of 2022.The transaction includes the first phase of the Centrum Południe project in Wroclaw, which consists of two joint office buildings, along with the last office building in the High5ive complex in Krakow. The leasable area in the transaction comprises of

Kamux Group Management Team Will Be Renewed and Strengthened

Kamux Corporation       Stock Exchange Release         January 4, 2022 at 08:00 (EET) Kamux Group Management Team Will Be Renewed and Strengthened The composition and responsibilities of Kamux Corporation’s Group Management Team will be renewed and strengthened to support the implementation of the updated strategy announced in March 2021. The strategic growth objective and internationalization require a new composition and expertise in the Group Management Team. The work of the Group Management Team will be re-organised, and in addition to the previously announced, there will be

Selvaag Bolig ASA: Status for buyback of own shares for employee share purchase programmes

As announced 6 December 2021 Selvaag Bolig ASA has initiated repurchase of up to 500 000 shares for the company’s incentive programmes. From 28 December 2021 through 3 January 2022 the company bought 66 095 shares at an average price of NOK 51.85. See the attached documents for detailed information about the transactions made. The buyback is carried out in accordance with the EU Market Abuse Regulation and Safe Harbour Regulation. Daily purchases are limited to a maximum of 25 per cent of the average daily volume traded the last 20 days. Following these transactions, Selvaag Bolig

UNION therapeutics announces enrollment of first patient in the IASOS Phase 2b study of oral orismilast in psoriasis patients

· IASOS[ ]is a Phase 2b dose-ranging study of oral orismilast in psoriasis patients with the purpose of identifying the appropriate dose-regimen for Phase 3 studies · Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properties also in development for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD)   Hellerup, Denmark, 4 January 2022 – UNION therapeutics A/S, a privately-held, multi-asset, clinical stage, biotechnology company focused on immunology and infectious diseases, today announced that the first patient has been enrolled in

Injeq’s IQ-Tip® needle receives CE certification – the Finnish innovation is ready for sales to the European market

Injeq Oy Press releaseJanuary 4, 2022 at 7:00 a.m. EET     The medical technology company Injeq’s development yielded the desired outcome after many years of efforts as the company’s IQ-Tip® needle received CE approval on December 21, 2021. The needle can be used in lumbar punctures from newborns to the elderly, treatment punctures of children with leukemia being one of the main indications. For medical devices, the CE certification translates to a marketing authorization in Europe. In other words, the company can expect a new era of growth as a result of the certification.

Acquires portfolio of 126 rental apartments in Umea

KlaraBo acquires a residential portfolio in Umea of a total of 126 rental apartments with an underlying property value of SEK 175 million. The total area amounts to approximately 8,700 sqm and the portfolio will be taken over today. The property portfolio is centrally located in Umea and fully rented. The rental value amounts to SEK 10.2 million and consists almost exclusively of residential and parking income. The acquisition is financed by bank loans and own cash. The acquisition also means that KlaraBo will establish itself in a new location for the company. "It feels good to

Nordea Bank Abp: Repurchase of own shares on 03.01.2022

Nordea Bank AbpStock exchange release – Changes in company’s own shares03.01.2022 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 03.01.2022 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading Number of Weighted average Total cost, EUR* **venue (MIC shares price / share, EUR* Code) **XSTO 350,560 10.85 3,804,588.74XHEL 262,351 10.87 2,851,125.73CEUX 299,740 10.86 3,255,532.36AQEU 50,992 10.86

Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease

Collaboration to evaluate imlifidase as potential pre-treatment prior to the administration of gene therapy in Pompe disease for patients with neutralizing antibodies (NAbs) to adeno-associated virus (AAV)Lund, Sweden January 3, 2022. Hansa Biopharma AB, “Hansa”, (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has entered into an agreement with Asklepios BioPharmaceutical, Inc. (“AskBio”), a fully integrated AAV gene therapy company and a fully owned subsidiary of Bayer AG dedicated to developing medicines that improve the

There are no items matching the current filter
There are no more items matching the current filter
Back to top